Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Denis, Garceau"'
Autor:
Chauret Nathalie, Denis Garceau
Publikováno v:
Pulmonary pharmacologytherapeutics. 56
BLU-5937 is a small molecule that was shown to be a potent, selective and non-competitive P2X3 homotrimeric receptor antagonist. P2X3 receptors are ATP ion-gated channels located on primary afferent neurons. ATP released from damaged or inflamed tiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ea5032237632cf730e5916f2afaef0
https://pubmed.ncbi.nlm.nih.gov/30902655
https://pubmed.ncbi.nlm.nih.gov/30902655
Autor:
John S. Sampalis, Steven H. Ferris, Daniel Saumier, Denis Garceau, D. Haine, Paul S. Aisen, Wan C. Lau, Joyce Suhy, Anh Duong, Serge Gauthier, Joonmi Oh
Publikováno v:
Archives of Medical Science : AMS
Introduction The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMEDTM) in mild-to-moderate Alzheimer’s disease (AD). Material and methods Double-blind, placebo-contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac66fabe0d7523fe6dc8fe5b95d45a71
https://doi.org/10.5114/aoms.2011.20612
https://doi.org/10.5114/aoms.2011.20612
Autor:
Denis Garceau, Joonmi Oh, John S. Sampalis, Anh Duong, Joyce Suhy, Steven H. Ferris, Paul S. Aisen, Daniel Saumier, W. Lau, D. Haine, Serge Gauthier
Publikováno v:
The Journal of Nutrition, Health and Aging. 13:550-557
The efficacy, safety and disease-modification of tramiprosate (homotaurine)were investigated in a recently completed large-scale Phase III clinical study in patients with mild to moderate Alzheimer’s disease (AD), the Alphase study. Disease-modific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed607b7dd1e8c375edfaf0c6b39653d6
https://doi.org/10.1007/s12603-009-0106-x
https://doi.org/10.1007/s12603-009-0106-x
Autor:
Bouke P. C. Hazenberg, Johan Bijzet, Pieter C. Limburg, Martha Skinner, Philip N. Hawkins, Irena Butrimiene, Avi Livneh, Olga Lesnyak, Evgeney L. Nasonov, Anna Filipowicz-Sosnowska, Ahmet Gül, Giampaolo Merlini, Piotr Wiland, Huri Özdogan, Peter D. Gorevic, Hédi Ben Maïz, Merrill D. Benson, Haner Direskeneli, Kalevi Kaarela, Denis Garceau, Wendy Hauck, Martin H. Van Rijswijk, null On behalf of the eprodisate for AA amyloidosis trial group
Publikováno v:
Amyloid: Journal of protein folding disorders, 14(2), 133-140. Taylor & Francis Ltd
Objective. Amyloid A protein quantification in fat tissue is a new immunochemical method for detecting AA amyloidosis, a rare but serious disease. The objective was to assess diagnostic performance in clinical AA amyloidosis.Methods. Abdominal subcut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f84170ee9643cd5c21db867fddd8e41
https://doi.org/10.1080/13506120701260224
https://doi.org/10.1080/13506120701260224
Autor:
Paul S. Aisen, Denis Garceau, P. Tremblay, Daniel Saumier, Julie Laurin, Richard Briand, F. Gervais
Publikováno v:
Neurology. 67:1757-1763
Background As a potential disease-modifying treatment for Alzheimer disease (AD), 3-amino-1-propanesulfonic acid (3APS) is a compound that binds to amyloid beta (Abeta), a toxic protein known to aggregate, leading to amyloid plaque deposition in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6abff9c4d122b609775542c8b636b89e
https://doi.org/10.1212/01.wnl.0000244346.08950.64
https://doi.org/10.1212/01.wnl.0000244346.08950.64
Autor:
Barry W. Rovner, Steven M. Greenberg, Denis Garceau, L. Creed Pettigrew, Jonathan Rosand, Alexander T. Schneider, Eric E. Smith, Kristin Schwab, Brian-Fred Fitzsimmons, Sam Gandy, M. Edip Gurol, Julie Laurin
Publikováno v:
Alzheimer Disease & Associated Disorders. 20:269-274
BACKGROUND AND PURPOSE No treatments have been identified to lower the risk of intracerebral hemorrhage due to cerebral amyloid angiopathy (CAA). A potential approach to prevention is the use of agents that interfere with the pathogenic cascade initi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7afc02e9bdddaaa5f70b0405805cc48
https://doi.org/10.1097/01.wad.0000213845.28624.f4
https://doi.org/10.1097/01.wad.0000213845.28624.f4
Publikováno v:
Cardiovascular Drugs and Therapy. 9:685-692
In the present study we investigated the relationship between pharmacodynamic and pharmacokinetic properties of the benzothiazepine-like calcium antagonists, clentiazem and diltiazem. Experiments were carried out in closed-chest anesthetized dogs, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8f04b9027157fadf41085f82ed7b2e
https://doi.org/10.1007/bf00878551
https://doi.org/10.1007/bf00878551
Autor:
Denis Garceau, David D. Waters
Publikováno v:
Journal of the American College of Cardiology. 21:964-970
Objectives. The efficacy and safety of clentiazem were assessed in 199 patients with stable angina in a dose-ranging, placebocontrolled, double-blind, parallel design study. Background. To date, this is the first large efficacy and safety study of cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f3ff20d67a6ba3a2236f1182da3d010
https://doi.org/10.1016/0735-1097(93)90354-4
https://doi.org/10.1016/0735-1097(93)90354-4
Publikováno v:
Canadian Journal of Physiology and Pharmacology. 70:983-989
The effects of TA-3090 (clentiazem) and nifedipine on basal sympathoadrenal activity and on the adrenal medullary response during splanchnic nerve stimulation were studied in dogs anesthetized with sodium pentobarbital. Plasma concentrations of epine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bf2ace279b3055fe84eea6c83c50040
https://doi.org/10.1139/y92-135
https://doi.org/10.1139/y92-135
Autor:
L. Thibault, Louis Dumont, Lesley Smith, Denis Garceau, Emile Levy, Ernest G. Seidman, Carole Garofalo
Publikováno v:
Experimental Biology and Medicine. 199:128-135
Recent interest has focused on findings that drugs used to lower blood pressure may adversely modify plasma lipids and lipoprotein metabolism. This observation may explain why pharmacologic control of hypertension has failed to reduce the incidence o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d7891252d8d28bc9757204617b92cc0
https://doi.org/10.3181/00379727-199-43340
https://doi.org/10.3181/00379727-199-43340